These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31958797)

  • 1. Predictive Value of Excision Repair Cross-Complementation Group 1 in the Response to Platinum-Based Chemotherapy in Esophageal Cancer: A Meta-Analysis.
    Zhuo ZG; Zhu YK; Deng HY; Li G; Luo J; Alai GH; Lin YD
    Oncol Res Treat; 2020; 43(4):160-169. PubMed ID: 31958797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.
    Takenaka T; Yano T; Kiyohara C; Miura N; Kouso H; Ohba T; Kometani T; Shoji F; Yoshino I; Maehara Y
    Lung Cancer; 2010 Jan; 67(1):101-7. PubMed ID: 19361884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERCC1 single nucleotide polymorphism C8092A, but not its expression is associated with survival of esophageal squamous cell carcinoma patients from Fujian province, China.
    Chen WH; Xin PL; Pan QX; Chen YY; Wang CR; Zhang ZS; Chen YF; Zhang CY; Cai WJ
    PLoS One; 2014; 9(9):e106600. PubMed ID: 25191856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
    Moxley KM; Benbrook DM; Queimado L; Zuna RE; Thompson D; McCumber M; Premkumar P; Thavathiru E; Hines L; Moore KN
    Gynecol Oncol; 2013 Aug; 130(2):377-82. PubMed ID: 23632208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.
    Steffensen KD; Waldstrøm M; Jeppesen U; Brandslund I; Jakobsen A
    Int J Gynecol Cancer; 2008; 18(4):702-10. PubMed ID: 17961161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of correlation between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer.
    KimCurran V; Zhou C; Schmid-Bindert G; Shengxiang R; Zhou S; Zhang L; Zhang J
    Adv Med Sci; 2011; 56(1):30-8. PubMed ID: 21536539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.
    Krawczyk P; Wojas-Krawczyk K; Mlak R; Kucharczyk T; Biernacka B; Milanowski J
    Folia Histochem Cytobiol; 2012 Apr; 50(1):80-6. PubMed ID: 22532140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
    Park DJ; Zhang W; Stoehlmacher J; Tsao-Wei D; Groshen S; Gil J; Yun J; Sones E; Mallik N; Lenz HJ
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):162-6. PubMed ID: 16224397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
    Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients.
    Avinash Tejasvi ML; Maragathavalli G; Putcha UK; Ramakrishna M; Vijayaraghavan R; Anulekha Avinash CK
    Indian J Pathol Microbiol; 2020; 63(4):538-543. PubMed ID: 33154302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy.
    Palomba G; Atzori F; Budroni M; Ombra M; Cossu A; Sini M; Pusceddu V; Massidda B; Frau B; Notari F; Ionta M; Palmieri G
    J Transl Med; 2014 Sep; 12():272. PubMed ID: 25253066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis.
    Wei HB; Lu XS; Shang LH; Xu G; Hu J; Che DH; Liu F; Wu Y; Zhang GM; Yu Y
    Arch Med Res; 2011 Jul; 42(5):412-20. PubMed ID: 21827803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
    Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.
    Liblab S; Vusuratana A; Areepium N
    Asian Pac J Cancer Prev; 2020 Jul; 21(7):1925-1929. PubMed ID: 32711417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin.
    van Huis-Tanja LH; Kweekel DM; Lu X; Franken K; Koopman M; Gelderblom H; Antonini NF; Punt CJ; Guchelaar HJ; van der Straaten T
    Mutat Res; 2014 Jan; 759():37-44. PubMed ID: 24220697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies.
    Qian YY; Liu XY; Wu Q; Song X; Chen XF; Liu YQ; Pei D; Shen LZ; Shu YQ
    Asian Pac J Cancer Prev; 2014; 15(19):8383-90. PubMed ID: 25339033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.